LI_18157
|
Pages: NA
|
Jun 2018 | 8424 Views
|
![]() ![]() |
|
Author's :
NA
|
Tables: NA
|
Charts: NA
|
Formats*:
![]() ![]() ![]() |
![]() ![]() |
Biopharmaceuticals are drugs produced from genetically modified source, which are mainly proteins and nucleic acids. According to IMS Health Market Prognosis, the total market size of pharmaceutical industry was approximately $962.1 billion in 2012. The market for the biopharmaceuticals drug was $149 billion in 2010. The factors driving the market are, increase in regulatory approvals for biotechnology products. One such product is the recombinant DNA-based products, which has high rates of approval from regulatory authorities. The opportunities of this market are the ageing population and increase in the number of diseases. The challenges of this market are the reimbursement and pricing policy that are the limiting factors in the launch of high priced drugs.
Key player profiled in the report are Pfizer, Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Abbott Laboratories, Inc., Bayer AG, Biocon Ltd, Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline, PLC. Johnson & Johnson, Inc., LG Life Sciences and Novartis AG
KEY BENEFITS
KEY MARKET SEGMENTS
BY THERAPEUTICS
BY PRODUCTS
KEY AUDIENCES
* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.
Enterprice
License/PDF
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high level data integrity, accurate analysis and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.